| scholarly article | Q13442814 |
| P50 | author | David A. Isenberg | Q42326409 |
| P2093 | author name string | S Chambers | |
| C Edwards | |||
| M Adler | |||
| G Neild | |||
| P2860 | cites work | Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans | Q24562483 |
| Adherence to Medication | Q28314923 | ||
| Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death | Q33403579 | ||
| The prognosis of lupus nephritis in African-Americans: a retrospective analysis | Q33491801 | ||
| Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. | Q34810008 | ||
| Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus | Q35549094 | ||
| Prognostic factors in lupus nephritis | Q36054839 | ||
| Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data | Q36748174 | ||
| Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity | Q39661179 | ||
| Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes | Q43970492 | ||
| Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis | Q46818795 | ||
| Factors associated with poor outcomes in patients with lupus nephritis | Q46840865 | ||
| Morbidity of systemic lupus erythematosus: role of race and socioeconomic status | Q46891297 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1144-1147 | |
| P577 | publication date | 2006-03-09 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period | |
| P478 | volume | 45 |
| Q38842399 | A study of the influence of ethnicity on serology and clinical features in lupus |
| Q34187295 | Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus |
| Q38366057 | Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q47218712 | Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. |
| Q33378474 | Conversion of discoid lupus to antiphospholipid syndrome and SLE. |
| Q36336024 | Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis |
| Q89316084 | Depression and medication nonadherence in childhood-onset systemic lupus erythematosus |
| Q33871960 | Depression, medication adherence, and service utilization in systemic lupus erythematosus |
| Q37292916 | Diabetes mellitus complicating systemic lupus erythematosus - analysis of the UCL lupus cohort and review of the literature |
| Q35082426 | End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. |
| Q60960470 | Engaging African ancestry participants in SLE clinical trials |
| Q37069392 | Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004 |
| Q37823786 | Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil |
| Q33578262 | Geographical distribution, a risk factor for the incidence of lupus nephritis in China |
| Q33533703 | Identification and validation of lupus nephritis cases using administrative data |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q57720999 | Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis |
| Q36540787 | Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry |
| Q34555870 | Increased Education is Associated with Decreased Compliance in an Urban Multi-Ethnic Lupus Cohort |
| Q63683444 | Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial |
| Q37533350 | Infiltrating CD16+ Are Associated with a Reduction in Peripheral CD14+CD16++ Monocytes and Severe Forms of Lupus Nephritis |
| Q35998043 | Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus |
| Q37462538 | Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study |
| Q43156843 | Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? |
| Q46194883 | Kidney allograft survival of African American and Caucasian American recipients with lupus. |
| Q53089425 | Long-term outcome in Japanese patients with lupus nephritis. |
| Q41616353 | Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. |
| Q38516182 | Longer duration of B cell depletion is associated with better outcome |
| Q43474417 | Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort |
| Q40619112 | Lupus nephritis in Latin American patients: 10-year results from a single medical center in Argentina |
| Q40223641 | Lupus nephritis: assessing the evidence, considering the future |
| Q92354998 | Management of refractory lupus nephritis: challenges and solutions |
| Q42688198 | Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context |
| Q46073827 | Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring |
| Q36386474 | Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus |
| Q37108959 | Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature |
| Q47136376 | Mental health care for youth with rheumatologic diseases - bridging the gap. |
| Q30655475 | Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort |
| Q34975939 | Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis |
| Q39036710 | Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry |
| Q38391828 | Outcomes in renal transplant recipients with lupus nephritis: experience at a single center |
| Q57329882 | Patients with familial and sporadic onset SLE have similar clinical profiles but vary profoundly by race |
| Q57805128 | Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis |
| Q44178069 | Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation |
| Q33455990 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort |
| Q35890096 | Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis |
| Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
| Q57945954 | References |
| Q37678723 | Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. |
| Q38479339 | Risk factors for renal disease in systemic lupus erythematosus and their clinical implications |
| Q35923416 | Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation |
| Q38641358 | Sustained remission in lupus nephritis: still a hard road ahead. |
| Q37754835 | Systemic lupus erythematosus and ethnicity: nature versus nurture or nature and nurture? |
| Q44148062 | Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage |
| Q51834159 | Systemic lupus erythematosus. |
| Q47116046 | T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients |
| Q89835229 | The Urinary Exosomal miRNA Expression Profile is Predictive of Clinical Response in Lupus Nephritis |
| Q37082037 | The frequency and outcome of lupus nephritis: results from an international inception cohort study |
| Q48878229 | Thirty years, five hundred patients: some lessons learned from running a lupus clinic |
| Q47102324 | Treatment Satisfaction in Systemic Lupus Erythematosus: Development of a Patient-Reported Outcome Measure |
| Q24202572 | Treatment for lupus nephritis |
| Q35019423 | Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. |
| Q42390564 | Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal Study |
Search more.